Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid.

Chunhua Ma,Xin Ye,Jing Li,Juncheng Zhang,Chuoji Huang,Ning Mu,Dongjiang Tang,Zhi Li,Rong Jiang,Renzhong Liu

doi:10.3389/fonc.2019.00938

Abstract

[This corrects the article DOI: 10.3389/fonc.2019.00628.].

Highlights

Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
Specialty section: This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
CSF and peripheral blood samples were collected for repeat genetic testing; the pressure of the ventriculoperitoneal shunt device was adjusted to 1.0, with afatinib dose increased to 40 mg qd

Summary

Introduction

Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid. Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid Specialty section: This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

Results

Conclusion